Published · 6 references

CJC-1295 (No DAC) vs IGF-1 LR3

CJC-1295 (No DAC) and IGF-1 LR3 are different molecules: CJC-1295 (No DAC) is built on human GHRH's first 29 residues; IGF-1 LR3 is an 83-residue analog of human IGF-1.

CJC-1295 (No DAC)

CJC-1295 (No DAC)

View CJC-1295 (No DAC)
vs
IGF-1 LR3

IGF-1 LR3

View IGF-1 LR3

Structure at a glance

Each chain as stored in the product database, one box per residue. The two are drawn separately; no alignment between them is implied.

CJC-1295 (No DAC) · 29 residues

IGF-1 LR3 · 83 residues

NH2: C-terminal amide. A raised D marks a D-amino acid. Codes are three-letter amino acid codes.

Chain length
CJC-1295 (No DAC)29 residues
IGF-1 LR383 residues
Molecular weight
CJC-1295 (No DAC)3,367.97 g/mol
IGF-1 LR39,111.45 g/mol

Drawn from the product database. Each measure's bars share one scale.

CJC-1295 (No DAC) vs IGF-1 LR3, compared
What it isAn analog of growth hormone-releasing hormone. Built on the GRF(1-29) backbone, with four amino acid substitutions.[1]An 83-residue protein carrying two changes to native human IGF-1: arginine in place of glutamate at position 3, and a 13-residue N-terminal extension.[2]
How they relateDifferent molecules from different parents. CJC-1295 (No DAC) is built on the first 29 residues of human growth hormone-releasing hormone, with four substitutions. IGF-1 LR3 carries two changes to native human IGF-1.[2]
CAS number863288-34-0143045-27-6
Molecular formulaC152H252N44O42C400H619N111O115S9
Molecular weight3,367.97 g/mol9,111.45 g/mol
SequenceTyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2Met-Phe-Pro-Ala-Met-Pro-Leu-Ser-Ser-Leu-Phe-Val-Asn-Gly-Pro-Arg-Thr-Leu-Cys-Gly-Ala-Glu-Leu-Val-Asp-Ala-Leu-Gln-Phe-Val-Cys-Gly-Asp-Arg-Gly-Phe-Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr-Gly-Ile-Val-Asp-Glu-Cys-Cys-Phe-Arg-Ser-Cys-Asp-Leu-Arg-Arg-Leu-Glu-Met-Tyr-Cys-Ala-Pro-Leu-Lys-Pro-Ala-Lys-Ser-Ala
Evidence baseIn the literature reviewed for CJC-1295 (No DAC), the pharmacokinetic findings were generated with the DAC form. Essentially uncharacterized in humans.[3]Measured findings in the literature reviewed for it: in vitro or animal work, none in people. No registered interventional trials in humans.[4] Almost every cited in vivo result comes from one consortium of its developers; independent replication is essentially absent.[5]
Regulatory statusNo approval history of any kind.IGF-1 LR3 holds no marketing authorization anywhere.
Compared head-to-head?No direct comparison found in PubMed (searched October 2026).[6]
Handling differenceCJC-1295 (No DAC) contains no sulfur, so it carries neither methionine nor cysteine. IGF-1 LR3 holds three disulfide bonds and three methionines; each methionine is an oxidation site.

How CJC-1295 (No DAC) and IGF-1 LR3 differ

CJC-1295 (No DAC) and IGF-1 LR3 are different molecules from different parents. CJC-1295 (No DAC) corresponds to the first 29 residues of human growth hormone-releasing hormone (GHRH), the stretch named GRF(1-29), with four of those positions substituted. It is also sold as Modified GRF(1-29), a name that states that construction more plainly. IGF-1 LR3 is an 83-residue protein carrying two changes to native human IGF-1.[2] Native IGF-1 is 70 residues long. Arginine takes the place of glutamate at position 3 of native IGF-1, and a 13-residue extension sits at the N-terminus.[2]

In the literature reviewed for CJC-1295 (No DAC), the pharmacokinetic findings, in rats and healthy volunteers, came from CJC-1295 with DAC, whose albumin-binding linker CJC-1295 (No DAC) lacks. CJC-1295 (No DAC) itself is essentially uncharacterized in humans.[3] The literature reviewed for CJC-1295 (No DAC) reports no human safety data for CJC-1295 (No DAC) itself.

In the literature reviewed for IGF-1 LR3, the measured findings are in vitro or animal work, none of it in people. There are no registered interventional trials of IGF-1 LR3.[4] That is not the same claim as saying it was never studied. Almost every in vivo result in that literature comes from one consortium of the compound's developers, and independent replication is essentially absent.[5] The literature reviewed for IGF-1 LR3 reports no human safety data.

Neither compound holds an approval. CJC-1295 (No DAC) has no approval history of any kind. IGF-1 LR3 holds no marketing authorization anywhere.

CJC-1295 (No DAC) contains no sulfur, so it carries neither methionine nor cysteine, and no disulfide or sulfoxide can form. IGF-1 LR3 holds three disulfide bonds, formed by six cysteines, and three methionines, two of them in its N-terminal extension. Each methionine is an independent oxidation site.

Have CJC-1295 (No DAC) and IGF-1 LR3 been compared directly?

No direct comparison of CJC-1295 (No DAC) with IGF-1 LR3 was found in a PubMed search run in October 2026.[6] That search covers PubMed only.

Read more on each compound

CJC-1295 (No DAC)

CJC-1295 (No DAC) ResearchMechanism, published findings, and the limits of the evidence.CJC-1295 (No DAC) ReferenceMolecular identity, reconstitution, storage, and purity verification.

IGF-1 LR3

IGF-1 LR3 ResearchMechanism, published findings, and the limits of the evidence.IGF-1 LR3 ReferenceMolecular identity, reconstitution, storage, and purity verification.

Frequently Asked Questions

Is CJC-1295 (No DAC) the same as IGF-1 LR3?+

No. CJC-1295 (No DAC) and IGF-1 LR3 are different molecules from different parents. CJC-1295 (No DAC) is built on the first 29 residues of human growth hormone-releasing hormone, with four substitutions. IGF-1 LR3 is an 83-residue protein carrying two changes to native human IGF-1.

References

  1. 1
    Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286. PMID 15817669.
  2. 2
    Original description, 1992. PMID 1378742.
  3. 3
    Dominikowski A, et al. Front Endocrinol (Lausanne) 2026. PMID 42395176. DOI 10.3389/fendo.2026.1822475. Narrative review.
  4. 4
    Per-compound registry searches for IGF-1 LR3. ClinicalTrials.gov API v2, query.intr and query.term for "IGF-1 LR3" and "LR3-IGF-1", both returning zero studies. Run 27 August 2026.
  5. 5
    Affiliation audit of the in vivo IGF-1 analogue papers cited in the IGF-1 LR3 research article. PubMed E-utilities efetch across the cited PMIDs. Run 27 August 2026.
  6. 6
    PubMed search via NCBI E-utilities, run 3 October 2026; records entered to 2 October 2026. Query: ("CJC-1295"[tiab] OR "CJC 1295"[tiab] OR "CJC1295"[tiab] OR "modified GRF"[tiab] OR "mod GRF"[tiab] OR "modGRF"[tiab] OR "tetrasubstituted"[tiab] OR "DAC-free"[tiab] OR "non-DAC"[tiab] OR "without DAC"[tiab] OR "no DAC"[tiab]) AND ("IGF-1 LR3"[tiab] OR "IGF-I LR3"[tiab] OR "LR3"[tiab] OR "LR(3)"[tiab] OR "long R3"[tiab] OR "long-R3"[tiab] OR "longR3"[tiab] OR "long R(3)"[tiab] OR "long-R(3)"[tiab] OR "longR(3)"[tiab] OR "R3-IGF-1"[tiab] OR "R3-IGF-I"[tiab] OR "R(3)-IGF-1"[tiab] OR "R(3)-IGF-I"[tiab] OR "Arg3"[tiab] OR "Arg(3)"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat]). 5 records; none was a direct comparison of the two compounds.

Related comparisons

Comparison

CJC-1295 (No DAC) vs CJC-1295 with DAC

CJC-1295 with DAC is a chemically modified form of CJC-1295 (No DAC); the DAC-free peptide is essentially uncharacterized in humans.

Read Comparison
Comparison

CJC-1295 (No DAC) vs Ipamorelin

CJC-1295 (No DAC) is a synthetic peptide built on human GHRH's first 29 residues; Ipamorelin is a synthetic five-residue peptide.

Read Comparison
Comparison

CJC-1295 (No DAC) vs Sermorelin

CJC-1295 (No DAC) is human GHRH's first 29 residues with four substitutions; Sermorelin is the unmodified fragment.

Read Comparison
All comparisons

Your Cart

Your cart is empty

Add some research compounds to get started.

Browse Products